Last reviewed · How we verify

NCT03594357

Cognitive Functions in Patients With Multiple Sclerosis

Completed Last updated 30 January 2019
What this trial tests

trial in Multiple Sclerosis in 137 participants. Completed in 24 December 2018.

Timeline
3 September 2018
Primary endpoint
21 December 2018
24 December 2018

Quick facts

Lead sponsorGazi University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment137
Start date3 September 2018
Primary completion21 December 2018
Estimated completion24 December 2018
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Gazi University

Who can join

Adults 18 to 65, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Approximately 65% of multiple sclerosis (MS) patients appear to have problems in their cognitive function. Long-term memory is one of the most frequently affected functions in MS patients. Many factors play a role in the deterioration of cognitive functions because of many symptoms of MS. The aim of this study is to investigate the relationship of cognitive function with physical factors such as balance, functional exercise capacity and personal factors such as fatigue level, mood, sleep quality in patients with MS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Gazi University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03594357.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing